Maryland's Biotech Sector Sees Funding and Innovation Surge
Maryland's life sciences industry is experiencing a wave of investment and new initiatives. Xcellon Biologics launched its "Xcellerate" program to help early-stage biotech startups, while AI-driven Ten63 Therapeutics closed a strategic financing round, bringing its total funding to over $45 million. Additionally, Altesa BioSciences secured an oversubscribed $75 million Series B for its chronic lung disease treatment, and University of Maryland researchers received $5.1 million in NIH grants for genomics research tools.
- The BioHealth Capital Region, which includes Maryland, is ranked as the #3 biopharma cluster in the U.S. by *Genetic Engineering & Biotechnology News*, consistently recognized for its high concentration of life sciences talent and proximity to federal agencies like the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). - From 2019 to 2023, Maryland's bioscience industry employment grew by 16.4% to over 52,000 jobs, outpacing the national average, with significant increases in research, testing, and medical laboratories. The state employs a high concentration of Ph.D. scientists and engineers, and the Washington-Baltimore area ranks third in the nation for life sciences R&D talent. - Ten63 Therapeutics, headquartered in North Carolina's Research Triangle Park, is developing its AI-powered BEYOND platform to simulate trillions of potential drug candidates. The platform aims to design treatments for previously "undruggable" targets, such as the Myc oncogene, which is implicated in 70% of all cancers. - A grant from the Gates Foundation is specifically supporting Ten63's development of affordable, small-molecule therapies for human papillomavirus (HPV), which is responsible for over 650,000 cancer cases annually worldwide. - Altesa BioSciences is led by CEO Dr. Brett Giroir, who previously served as the acting FDA Commissioner under the Trump administration. The company's lead drug, vapendavir, is an oral antiviral that targets the human rhinovirus, a primary trigger of severe flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD). - Vapendavir was licensed by Altesa from Vaxart in 2021 after it had been previously developed by Aviragen Therapeutics, where it failed a Phase 2 trial for asthma treatment in 2017. Altesa is now advancing it for COPD, with a large-scale Phase 2b trial expected to begin in the second quarter of 2026. - Xcellon Biologics' Xcellerate Program is specifically designed to support seed and pre-Series A startups that face difficulty securing capital. It provides these early-stage companies with access to costly development services for complex biologics, including antibody generation and analytical support, at reduced or at-cost rates to help them reach critical IND-enabling milestones.
